Search for Clinical Trial Results
Immunoblastic Lymphadenopathy - 269 Studies Found
Status | Study |
Completed |
Study Name: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Condition:
|
Terminated |
Study Name: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Condition:
|
Completed |
Study Name: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Condition:
|
Recruiting |
Study Name: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Condition:
Interventions: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases |
Completed |
Study Name: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Condition:
|
Completed |
Study Name: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Condition: Untreated T-cell Angioimmunoblastic Lymphoma Date: 2005-09-12 Interventions:
|
Completed |
Study Name: Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Condition: Lymphoma Date: 2009-08-12 Interventions:
|
Terminated |
Study Name: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Condition: Lymphoma Date: 2003-10-03 Interventions: Drug: cyclosporine Cyclosporine doses will be based on actual body weight unless actual body weight is & |
Recruiting |
Study Name: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Condition:
|
Completed |
Study Name: Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Condition:
|